New drug aims to tame dangerous immune storms after cancer transplants
NCT ID NCT05823571
Summary
This early-stage study is testing whether a drug called itacitinib can make stem cell transplants safer for older patients with blood cancers. The goal is to prevent a severe, potentially life-threatening immune reaction called cytokine release syndrome (CRS) that can occur after the transplant. Researchers also hope the drug will allow patients to take fewer immune-suppressing medications after the procedure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.